» Articles » PMID: 26402225

Placental Growth Factor Promotes Metastases of Ovarian Cancer Through MiR-543-regulated MMP7

Overview
Date 2015 Sep 25
PMID 26402225
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Elucidation of the molecular mechanisms underlying ovarian cancer (OC) cell invasion and migration may provide important evidence for developing efficient therapy. Recently, Matrix metalloproteinase (MMP) has been shown to be regulated by vascular endothelial growth factor family members, especially placental growth factor (PLGF), as a potential mechanism underlying cancer invasion. Here, we studied the molecular relationship between PLGF and MMP7 in the OC.

Methods: We examined the levels of PLGF and MMP7 in the resected OC specimens and compared to paired adjacent non-tumor ovarian tissue. We also examined the correlation between PLGF and MMP7. We modified PLGF levels in a human OC cell line, OVCAR3, and analyzed the effects on MMP7. Prediction of microRNA (miRNA) binding to 3'-UTR of MMP7 mRNA was performed by bioinformatics analyses and confirmed by a dual luciferase reporter assay using miR-543-modifed OC cells. The levels of miR-543 were examined in the OC specimens, and the correlation between miR-543 and PLGF or MMP7 was performed.

Results: PLGF and MMP7 both significantly increased in the OC specimens, compared to paired adjacent non-tumor ovarian tissue. PLGF significantly increased MMP7 in the OC cells at protein level, but not at mRNA level. In OC cells, PLGF significantly decreased the levels of miR-543, which suppressed the translation of MMP7 mRNA via 3'-UTR binding. In OC specimen, miR-543 significantly decreased, compared to paired adjacent non-tumor ovarian tissue. An inverse correlation was detected between the levels of miR-543 and PLGF or MMP7 in the OC specimens.

Conclusion: MiR-543 inhibits translation of MMP7 through binding to the 3'-UTR of MMP7 mRNA in OC. PLGF suppresses miR-543, which activates MMP7-mediated cancer invasion.

Citing Articles

LncRNA SNHG6 role in clinicopathological parameters in cancers.

Khan K, Irfan M, Sattar A, Faiz M, Rahman A, Athar H Eur J Med Res. 2023; 28(1):363.

PMID: 37735423 PMC: 10515066. DOI: 10.1186/s40001-023-01358-2.


Metamorphic Effect of Angiogenic Switch in Tumor Development: Conundrum of Tumor Angiogenesis Toward Progression and Metastatic Potential.

Moshe D, Baghaie L, Leroy F, Skapinker E, Szewczuk M Biomedicines. 2023; 11(8).

PMID: 37626639 PMC: 10452636. DOI: 10.3390/biomedicines11082142.


Long noncoding RNA SNHG6 promotes the malignant phenotypes of ovarian cancer cells via miR-543/YAP1 pathway.

Su M, Huang P, Li Q Heliyon. 2023; 9(5):e16291.

PMID: 37234669 PMC: 10208841. DOI: 10.1016/j.heliyon.2023.e16291.


Approaches Toward Targeting Matrix Metalloproteases for Prognosis and Therapies in Gynecological Cancer: MicroRNAs as a Molecular Driver.

Pandit A, Begum Y, Saha P, Srivastava A, Swarnakar S Front Oncol. 2022; 11:720622.

PMID: 35145899 PMC: 8821656. DOI: 10.3389/fonc.2021.720622.


LncRNA MEG3 inhibits the development of nasopharyngeal carcinoma by sponging miR-543 targeting KLF4.

Ning J, Zhang L, Guo H, Zhou S, Sun X, Bao W Transl Cancer Res. 2022; 9(2):958-971.

PMID: 35117441 PMC: 8798555. DOI: 10.21037/tcr.2019.12.41.